Vaxcyte (PCVX) Revenue & Revenue Breakdown
Vaxcyte Revenue Highlights
Main Segment (Y)
Pneumococcal Conjugate Vaccine
Main Geography (Y)
Pneumococcal Conjugate Vaccine
Vaxcyte Revenue by Period
Vaxcyte Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Vaxcyte generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Vaxcyte Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $14.45M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Vaxcyte generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Vaxcyte Revenue Breakdown
Vaxcyte Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 | Dec 20 |
|---|---|---|
| Pneumococcal Conjugate Vaccine | $7.00B | $7.00B |
Vaxcyte's latest annual revenue breakdown by segment (product or service), as of Dec 21: Pneumococcal Conjugate Vaccine (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 22 | Mar 22 | Mar 21 | Jun 20 |
|---|---|---|---|---|
| Pneumococcal Conjugate Vaccine | $7.00B | $7.00B | $7.00B | $7.00B |
Vaxcyte's latest quarterly revenue breakdown by segment (product or service), as of Jun 22: Pneumococcal Conjugate Vaccine (100.00%).
Vaxcyte Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 20 |
|---|---|---|
| Pneumococcal Conjugate Vaccine | $7.00B | $7.00B |
Vaxcyte's latest annual revenue breakdown by geography, as of Dec 21: Pneumococcal Conjugate Vaccine (100.00%).
Quarterly Revenue by Country
| Country | Jun 22 | Mar 22 | Mar 21 | Jun 20 |
|---|---|---|---|---|
| Pneumococcal Conjugate Vaccine | $7.00B | $7.00B | $7.00B | $7.00B |
Vaxcyte's latest quarterly revenue breakdown by geography, as of Jun 22: Pneumococcal Conjugate Vaccine (100.00%).
Vaxcyte Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
| TECH | Bio-Techne | $1.16B | $303.43M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| IMCR | Immunocore | $249.43M | $75.40M |
| STRO | Sutro Biopharma | $153.73M | $13.01M |
| TVTX | Travere Therapeutics | $145.24M | $62.90M |
| ACLX | Arcellx | $110.32M | $27.38M |
| MRUS | Merus | $43.95M | $11.77M |
| LQDA | Liquidia | $17.49M | $2.97M |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| DICE | DICE Therapeutics | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| VTYX | Ventyx Biosciences | - | - |
| LRMR | Larimar Therapeutics | - | - |
| AKRO | Akero Therapeutics | - | - |
PCVX Revenue FAQ
What is Vaxcyte’s yearly revenue?
Vaxcyte's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. PCVX's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Vaxcyte’s quarterly revenue?
Vaxcyte's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). PCVX's quarterly revenue for Q4 2023 was $14.45M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Vaxcyte’s revenue growth rate?
Vaxcyte's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.
What are Vaxcyte’s revenue streams?
Vaxcyte's revenue streams in c 21 are Pneumococcal Conjugate Vaccine
What is Vaxcyte’s main source of revenue?
For the fiscal year ending Dec 21, the largest source of revenue of Vaxcyte was Pneumococcal Conjugate Vaccine. This segment made a revenue of $7B, representing 100.00% of the company's total revenue.